This PubMed entry records a Phase 3 clinical trial titled "Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia" published in the New England Journal of Medicine (N Engl J Med). The citation lists the e-publication date as 2026 Jun 28 and the journal issue as 2026 Sep 3;395(9):859-869. The PubMed record provides the bibliographic identifiers: PMID 42370681 and DOI 10.1056/NEJMoa2604565. The entry is categorized as a Clinical Trial in the PubMed metadata.
The article title indicates the primary investigational agent and population: a Phase 3 study of Oral Infigratinib in pediatric patients with achondroplasia. The PubMed record makes clear the primary focus is a late‑phase interventional trial in children affected by this condition. The displayed PubMed content does not include the trial abstract or outcome summaries in the clipped source provided here.
The author list is extensive and led by Ravi Savarirayan, with numerous coauthors representing academic, clinical, and industry affiliations. Named contributors include clinicians and investigators such as Julie Hoover‑Fong, Melita Irving, Paul Arundel, Josep Maria de Bergua, and many others. Several authors are affiliated with BridgeBio Pharma (San Francisco), indicating industry participation alongside academic investigators. The presence of a broad, multinational authorship suggests a collaborative effort across multiple centers and countries.
Affiliations recorded in the PubMed entry span institutions in Australia, North America, Europe, and Asia. Examples include Murdoch Children's Research Institute (Melbourne), Johns Hopkins University (Baltimore), Guy's and St. Thomas' NHS Foundation Trust (London), Centre Hospitalier Universitaire Sainte‑Justine (Montreal), Oslo University Hospital, Haukeland University Hospital (Bergen), KK Women's and Children's Hospital (Singapore), Hospital de Pediatría Garrahan (Buenos Aires), and multiple other pediatric hospitals and university centers. Industry affiliations are listed for BridgeBio Pharma in San Francisco. The PubMed entry therefore documents a geographically diverse set of contributing centers.
The PubMed record provides direct bibliographic links, including the DOI (10.1056/NEJMoa2604565) and a full text link pointing to the NEJM/Atypon platform. Readers with institutional access or journal subscription can retrieve the full article through those links. The PubMed page also documents the PMID (42370681) which can be used for indexing and retrieval.
The PubMed excerpt supplied here contains comprehensive bibliographic metadata (title, authors, affiliations, publication date, DOI, PMID) but does not include the article abstract text or detailed trial data within the clipped content. Key methodological and outcome information that is typically required for clinical appraisal — including trial design specifics, eligibility criteria, randomization and blinding, sample size, dosing regimens, primary and secondary endpoints, efficacy results, safety and adverse‑event data, and statistical analysis — are not present in the provided PubMed snippet. Those critical details are not reported in this source text and therefore cannot be restated here.
The PubMed record confirms that a Phase 3 study of Oral Infigratinib in children with achondroplasia has been published in a high‑impact peer‑reviewed journal. However, clinicians, researchers, and other stakeholders should consult the NEJM full text (via the DOI or full‑text link) to access the trial’s methods, results, statistical analyses, and supplementary materials before drawing clinical or research conclusions.
For appraisal and application:
All statements above are based solely on the bibliographic record and metadata shown on PubMed for PMID 42370681. The PubMed entry confirms the publication and authorship but does not supply the abstract or the trial data in the supplied content. Any interpretation of efficacy, safety, or practice implications requires direct review of the complete article and supporting materials, which are accessible through the DOI link to the NEJM platform.